Patient Recruitment/Retention Featured Articles

81. A Vision For Inclusion: Designing Trials That Benefit Visually Impaired Patients 8/30/2024

    Ocugen CMO Huma Qamar, MD, MPH, CMI contends that whether targeting vision-related conditions or other medical needs, sponsors must design trials that ensure vision-impaired patients are included.

82. The DCT Revolution Is Over… Vive La DCT Evolution! 8/29/2024

    The DCT ecosystem has matured significantly to include service providers with more real-world experience and advanced tools, plus a mindset of initiative versus reaction. Numerous regulators have released or updated DCT guidance documents in recent years, too, putting the onus on the industry to provide actionable feedback on those drafts.

83. The DEI Dilemma: Separate Teams Or Embedded Methods? 8/28/2024

    Denise Bronner, PH.D. examines the advantages and drawbacks of separate, dedicated DEI teams and diversity roles embedded across functional areas.

84. Summing Up The FDA's Long-Anticipated Draft Guidance On Diversity Action Plans 8/26/2024

    Life sciences attorney Marylana Saadeh Helou summarizes the FDA's draft guidance on Diversity Action Plans (DAPs).

85. How Sponsors Can Make It Easier For Rare Disease Patients And Families To Participate In Trials 8/22/2024

    New research highlights several significant challenges sponsors encounter when conducting clinical trials in rare neurological disorders.

86. Individual Participant Data Return Solutions And Strategies 8/22/2024

    Paula Boyles, external clinical trial data-sharing program lead for Pfizer and TransCelerate BioPharma member, shares the benefits of and strategies for individual patient data return (iPDR).

87. Operationalizing A Diversity Action Plan That Makes An Impact 8/19/2024

    In part two of this series on creating a diversity action plan (DAP), Elevate Advocacy's Devra Densmore shares a detailed plan for creating a DAP that meets FDA expectations.

88. The Future Of MDMA-Assisted Therapy After FDA Rejection — Where Do We Go Now? 8/16/2024

    After the recent FDA rejection of MDMA-assisted therapy for PTSD, psychedelic drug developers and mental health experts alike are asking (and answering), "Where do we go now?"

89. Creating More Equitable Clinical Trials With Health Systems Science 8/15/2024

    Belmont University Center for Health Systems Science Chair Douglas P. Slakey, MD, MPH explains how using health systems science to inform clinical trial design, implementation, and interpretation is crucial for achieving more equitable and effective patient outcomes.

90. Diversity Action Plan (DAP): Creating An Ecosystem For Success 8/12/2024

    In part one of this two-part series, Elevate Advocacy Founder Devra Densmore explores how to create an ecosystem in which a successful diversity action plan (DAP) can be written and executed.